CAS
JAZZ icon

CTC Alternative Strategies’s Jazz Pharmaceuticals JAZZ Stock Holding History

CTC Alternative Strategies’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,500
Closed -$241K – 153
2014
Q3 		$241K Buy
+1,500
New +$231K 0.44% 43
2013
Q3 		– Sell
-6,100
Closed -$419K – 143
2013
Q2 		$419K Buy
+6,100
New +$373K 0.11% 78

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTC Alternative Strategies's JAZZ Position: Q4 2014 in Review

CTC Alternative Strategies sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2014, closing a stake of 1,500 shares — an estimated $241K sold.

CTC Alternative Strategies first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $419K in Q2 2013. 357 funds tracked by Wall St. Rank hold JAZZ as of Q4 2014.

  • CTC Alternative Strategies reported no remaining Jazz Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • CTC Alternative Strategies sold 1,500 Jazz Pharmaceuticals shares in Q4 2014, an estimated $241K.
  • CTC Alternative Strategies first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • CTC Alternative Strategies's Jazz Pharmaceuticals position peaked at $419K in Q2 2013.
  • 357 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2014.

Based on CTC Alternative Strategies's 13F filing for Q4 2014, filed 29 Jan 2015.